Expanding Global Pharmaceutical R&D Will Unlock Blockbuster Royalty Deals

Published
15 Apr 25
Updated
08 Aug 25
AnalystHighTarget's Fair Value
US$55.00
33.7% undervalued intrinsic discount
08 Aug
US$36.46
Loading
1Y
36.8%
7D
-1.8%

Author's Valuation

US$55.0

33.7% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 12%

Shared on30 Apr 25

AnalystHighTarget has increased profit margin from 26.1% to 64.4% and decreased future PE multiple from 31.2x to 12.7x.

Shared on23 Apr 25
Fair value Increased 16%

AnalystHighTarget made no meaningful changes to valuation assumptions.